Literature DB >> 2741845

Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome.

M Mintz1, R Rapaport, J M Oleske, E M Connor, M R Koenigsberger, T Denny, L G Epstein.   

Abstract

The cytokine tumor necrosis factor (TNF) was assayed in the sera (n = 31) and cerebrospinal fluid (n = 26) of children with acquired immunodeficiency syndrome, using a competitive radioimmunoassay. Elevated serum levels of TNF were found in 15 (79%) of 19 patients with progressive encephalopathy (PE), compared with 1 (8%) of 12 patients without neurologic involvement. There was a significant association of PE with elevated serum TNF levels. Conversely, of 16 patients with elevated serum TNF levels, 15 (94%) were found to have PE, and of 8 patients with serum TNF levels greater than 100 pg/ml, all 8 (100%) had PE. No association was found between cerebrospinal fluid levels of TNF and PE. Neither serum nor cerebrospinal fluid TNF levels correlated with the degree of cachexia. These data suggest that circulating TNF may be responsible for the myelin damage that occurs in human immunodeficiency virus type 1-associated PE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741845     DOI: 10.1001/archpedi.1989.02150190021012

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  29 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Immunological treatments for autism.

Authors:  S Gupta
Journal:  J Autism Dev Disord       Date:  2000-10

3.  Human immunodeficiency virus type 1 infection of neural xenografts.

Authors:  T A Cvetkovich; E Lazar; B M Blumberg; Y Saito; T A Eskin; R Reichman; D A Baram; C del Cerro; H E Gendelman; M del Cerro
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

4.  Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine.

Authors:  M Roederer; F J Staal; P A Raju; S W Ela; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

Authors:  A Bergamini; M Capozzi; L Ghibelli; L Dini; A Salanitro; G Milanese; T Wagner; S Beninati; C D Pesce; C Amici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

6.  In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Authors:  Y Sasaki; A Blanchard; H L Watson; S Garcia; A Dulioust; L Montagnier; M L Gougeon
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Tungsten treatment prevents tumor necrosis factor-induced injury of brain endothelial cells.

Authors:  L S Terada; I R Willingham; D M Guidot; G N Shibao; G W Kindt; J E Repine
Journal:  Inflammation       Date:  1992-02       Impact factor: 4.092

8.  Monocyte adhesion to endothelium in simian immunodeficiency virus-induced AIDS encephalitis is mediated by vascular cell adhesion molecule-1/alpha 4 beta 1 integrin interactions.

Authors:  V G Sasseville; W Newman; S J Brodie; P Hesterberg; D Pauley; D J Ringler
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

9.  AIDS-related optic neuropathy: a histological, virological and ultrastructural study.

Authors:  A A Sadun; J S Pepose; M C Madigan; K A Laycock; W N Tenhula; W R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

10.  Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

Authors:  A Kalinkovich; G Livshits; H Engelmann; N Harpaz; R Burstein; M Kaminsky; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.